The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Cited by
Sorted by citations
Items 401–500 of 1,005
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 88
International Journal of Scientific Research
Baruah, A., Das, S., Dutta, A., Das, B., Sharma, T., & Hazarika, M. (2025) · International Journal of Scientific Research · doi:10.15373/22778179 · Cited by 87
Ding, M., Jiang, C., Zhang, Y., Zhao, J., Han, B., & Xia, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1516-1 · Cited by 86
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer
Shukla, S. K., Zhang, X., Niknafs, Y. S., Xiao, L., Mehra, R., Cieslik, M. P., Ross, A. E., Schaeffer, E. M., Malik, B., Guo, S., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.001 · Cited by 86
Self-citationGreif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Kerbs, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2344 · Cited by 88
Tousignant, K. D., Rockstroh, A., Fard, A. T., Lehman, M., Wang, C., McPherson, S. J., Philp, L., Bartoniček, N., Dinger, M. E., Nelson, C. C., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1147 · Cited by 85
Munkley, J., Oltean, S., Vodák, D., Wilson, B. T., Livermore, K. E., Zhou, Y., Star, E., Floros, V. I., Johannessen, B., Knight, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6024 · Cited by 85
Tian, T. V., Tomavo, N., Huot, L., Flourens, A., Bonnelye, E., Flajollet, S., Hot, D., Leroy, X., de Launoit, Y., & Duterque‐Coquillaud, M. (2013) · Oncogene · doi:10.1038/onc.2013.176 · Cited by 92
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer
Jin, X., Wang, J., Gao, K., Zhang, P., Yao, L., Tang, Y., Tang, L., Ma, J., Xiao, J., Zhang, E., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006748 · Cited by 87
Chi, K. N., Barnicle, A., Sibilla, C., Lai, Z., Corcoran, C., Barrett, J. C., Adelman, C. A., Qiu, P., Easter, A., Dearden, S. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0931 · Cited by 85
Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer
Rodrigues, L. U., Rider, L. C., Nieto, C., Romero, L. M., Karimpour‐Fard, A., Loda, M. F., Lucia, M. S., Wu, M., Shi, L., Cimic, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1596 · Cited by 84
TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis
Singh, R., Karri, D., Shen, H., Shao, J., Dasgupta, S., Huang, S., Edwards, D. P., Ittmann, M., O’Malley, B. W., & Yi, P. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96060 · Cited by 84
Shukla, S., Cyrta, J., Murphy, D. A., Walczak, E. G., Ran, L., Agrawal, P. K., Xie, Y., Chen, Y., Wang, S., Zhan, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.008 · Cited by 83
A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
Lang, S., Swift, S. L., White, H., Misso, K., Kleijnen, J., & Quek, R. G. W. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4842 · Cited by 85
Casalino, L., & Verde, P. (2020) · Genes · doi:10.3390/genes11080922 · Cited by 83
Molecular mechanisms underlying the development of neuroendocrine prostate cancer
Liu, S., Alabi, B. R., Yin, Q., & Stoyanova, T. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.007 · Cited by 84
Mills, A. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026450 · Cited by 83
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Wyatt, A. W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D. M., Johnston, R. L., Haegert, A., Li, E., et al. (2014) · Genome Biology · doi:10.1186/s13059-014-0426-y · Cited by 82
Self-citationChen, J., Zhang, D., Yan, W., Yang, D., & Shen, B. (2013) · BioMed Research International · doi:10.1155/2013/901578 · Cited by 86
Coarfa, C., Fiskus, W. C., Eedunuri, V. K., Rajapakshe, K., Foley, C., Chew, S. A., Shah, S. S., Geng, C., Shou, J., Mohamed, J. S., et al. (2015) · Oncogene · doi:10.1038/onc.2015.295 · Cited by 82
Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer
Zhao, Y., Tindall, D. J., & Huang, H. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8389 · Cited by 85
Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications
Chen, H., & Chen, R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00113 · Cited by 85
Lotan, T. L., Heumann, A., Rico, S. D., Hicks, J. L., Lecksell, K., Koop, C., Sauter, G., Schlomm, T., & Simon, R. (2017) · Oncotarget · doi:10.18632/oncotarget.19217 · Cited by 82
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121497 · Cited by 82
Schörghofer, D., Kinslechner, K., Preitschopf, A., Schütz, B., Röhrl, C., Hengstschläger, M., Stangl, H., & Mikula, M. (2015) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-015-0087-z · Cited by 81
Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K. G., de Barros, H. A., Alkemade, M., Bekers, E. M., Severson, T., Sanders, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0576 · Cited by 83
SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer
Audet‐Walsh, É., Vernier, M., Yee, T., Laflamme, C., Li, S., Chen, Y., & Giguère, V. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0410 · Cited by 82
Flores‐Morales, A., Bergmann, T., Lavallee, C., Batth, T. S., Lin, D., Lerdrup, M., Friis, S., Bartels, A., Kristensen, G., Krzyzanowska, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0729 · Cited by 82
Schoenborn, J. R., Nelson, P., & Fang, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3606 · Cited by 86
Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer
Ashikari, D., Takayama, K., Tanaka, T., Suzuki, Y., Obinata, D., Fujimura, T., Urano, T., Takahashi, S., & Inoue, S. (2017) · Oncogene · doi:10.1038/onc.2017.225 · Cited by 80
Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
Ci, X., Hao, J., Dong, X., Choi, S. Y. C., Xue, H., Wu, R., Qu, S., Gout, P. W., Zhang, F., Haegert, A. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3677 · Cited by 82
Faugeroux, V., Pailler, E., Oulhen, M., Déas, O., Brullé, L., Hervieu, C., Marty, V., Alexandrova, K., Andree, K., Stoecklein, N. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15426-2 · Cited by 87
Nowak, D. G., Cho, H., Herzka, T. M., Watrud, K. E., DeMarco, D. V., Wang, V. M.-Y., Şentürk, Ş., Fellmann, C., Ding, D., Beinortas, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1113 · Cited by 83
Srivastava, A., Ritesh, K. C., Tsan, Y.-C., Liao, R., Su, F., Cao, X., Hannibal, M., Keegan, C. E., Chinnaiyan, A. M., Martin, D. M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv499 · Cited by 85
Self-citationAndrogen–glucocorticoid interactions in the era of novel prostate cancer therapy
Narayanan, S., Srinivas, S., & Feldman, D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.254 · Cited by 84
A census of pathway maps in cancer systems biology
Kuenzi, B. M., & Ideker, T. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0240-7 · Cited by 82
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 81
Transcriptional network of androgen receptor in prostate cancer progression
Takayama, K., & Inoue, S. (2013) · International Journal of Urology · doi:10.1111/iju.12146 · Cited by 83
Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer
Yang, Y. A., & Yu, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.01.003 · Cited by 84
Ramos‐Montoya, A., Lamb, A. D. G., Russell, R., Carroll, T., Jurmeister, S., Galeano-Dalmau, N., Massie, C. E., Boren, J., Bon, H., Theodorou, V., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303581 · Cited by 79
Petrovics, G., Li, H., Stümpel, T., Tan, S., Young, D., Katta, S., Li, Q., Ying, K., Klocke, B., Ravindranath, L., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.10.028 · Cited by 79
Linch, S. N., Kasiewicz, M. J., McNamara, M. J., Hilgart-Martiszus, I., Farhad, M. E., & Redmond, W. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510518113 · Cited by 79
Tsai, H. K., Lehrer, J. M., Alshalalfa, M., Erho, N., Davicioni, E., & Lotan, T. L. (2017) · BMC Cancer · doi:10.1186/s12885-017-3729-z · Cited by 79
SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression
Zhang, J., Chen, M., Zhu, Y., Dai, X., Dang, F., Ren, J., Ren, S., Shulga, Y. V., de Beça, F. F., Gan, W., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.11.035 · Cited by 80
SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression
Kawamura, N., Nimura, K., Saga, K., Ishibashi, A., Kitamura, K., Nagano, H., Yoshikawa, Y., Ishida, K., Nonomura, N., Arisawa, M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3965 · Cited by 78
Palanisamy, N., Yang, J., Shepherd, P. D. A., Li-Ning-Tapia, E. M., Labanca, E., Manyam, G. C., Ravoori, M. K., Kundra, V., Araujo, J. C., Efstathiou, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0479 · Cited by 78
Self-citationShi, W. M., Wang, Y., Zhao, Y., Kim, J. J., Li, H., Meng, C., Chen, F., Zhang, J., Mak, D. H. F., Van, V., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6724 · Cited by 80
Farrell, J. S., Petrovics, G., McLeod, D. G., & Srivastava, S. K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815510 · Cited by 78
Androgen-regulated metabolism and biosynthesis in prostate cancer
Barfeld, S. J., Itkonen, H. M., Urbanucci, A., & Mills, I. G. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0515 · Cited by 78
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
Komura, K., Yoshikawa, Y., Shimamura, T., Chakraborty, G., Gerke, T. A., Hinohara, K., Chadalavada, K., Jeong, S. H., Armenia, J., Du, S.-Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96769 · Cited by 80
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
Nizialek, E. A., & Antonarakis, E. S. (2020) · Cancer Management and Research · doi:10.2147/cmar.s227033 · Cited by 82
Predicting master transcription factors from pan-cancer expression data
Reddy, J., Fonseca, M. A., Corona, R. I., Nameki, R. A., Dezem, F. S., Klein, I. A., Chang, H. S. Y., Chaves‐Moreira, D., Afeyan, L. K., Malta, T. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6123 · Cited by 82
Selvaraj, N., Kedage, V., & Hollenhorst, P. C. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0089-7 · Cited by 77
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78
Self-citationTET2 binds the androgen receptor and loss is associated with prostate cancer
Nickerson, M. L., Das, S., Im, K. M., Turan, S., Berndt, S. I., Li, H., Lou, H., Brodie, S. A., Billaud, J.-N., Zhang, T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.376 · Cited by 78
Tilki, D., Schaeffer, E. M., & Evans, C. P. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.11.013 · Cited by 80
HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncologyPreprint
Shrestha, R., Hodzic, E., Sauerwald, T., Dao, P., Wang, K., Yeung, J., Anderson, S. A., Vandin, F., Haffari, G., Collins, C. C., et al. (2017) · Genome Research · doi:10.1101/gr.221218.117 · Cited by 77
Self-citationTranscriptional Regulation in Prostate CancerPreprint
Labbé, D. P., & Brown, M. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030437 · Cited by 80
Lotan, T. L., Wei, W., Morais, C. L., Hawley, S. T., Fazli, L., Hurtado‐Coll, A., Troyer, D. A., McKenney, J. K., Simko, J. P., Carroll, P. R., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.07.005 · Cited by 76
Pal, S. K., Patel, J., He, M., Foulk, B., Kraft, K., Smirnov, D. A., Twardowski, P. W., Kortylewski, M., Bhargava, V., & Jones, J. O. (2017) · Cancer · doi:10.1002/cncr.31161 · Cited by 78
Tan, S., Petrovics, G., & Srivastava, S. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041255 · Cited by 77
Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities
Powell, I. J., & Bollig-Fischer, A. B. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1039 · Cited by 76
Antonarakis, E. S., Chandhasin, C., Osbourne, E., Luo, J., Sadar, M. D., & Perabo, F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0161 · Cited by 77
Chen, R., Zeng, X., Zhang, R., Huang, J., Kuang, X., Yang, J., Liu, J., Tawfik, O. W., Thrasher, J. B., & Li, B. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.05.011 · Cited by 75
Role of the DNA damage response in prostate cancer formation, progression and treatment
Zhang, W., van Gent, D. C., Incrocci, L., van Weerden, W. M., & Nonnekens, J. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0153-2 · Cited by 79
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 78
Jiang, N., Hjorth-Jensen, K., Hekmat, O., Iglesias‐Gato, D., Kruse, T., Wang, C., Wei, W., Ke, B., Yan, B., Niu, Y., et al. (2014) · Oncogene · doi:10.1038/onc.2014.206 · Cited by 76
NFI Transcription Factors Interact with FOXA1 to Regulate Prostate-Specific Gene Expression
Grabowska, M. M., Elliott, A. D., DeGraff, D. J., Anderson, P. D., Anumanthan, G., Yamashita, H., Sun, Q., Friedman, D. B., Hachey, D. L., Yu, X., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1213 · Cited by 75
Persistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 77
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Clermont, P., Crea, F., Chiang, Y. T., Lin, D., Zhang, A. X. W., Wang, J. Z. L., Parolia, A., Wu, R. C., Xue, H., Wang, Y., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0182-9 · Cited by 77
Liu, S., Kumari, S., Hu, Q., Senapati, D., Venkadakrishnan, V. B., Wang, D., DePriest, A. D., Schlanger, S. E., Ben‐Salem, S., Valenzuela, M. M., et al. (2017) · eLife · doi:10.7554/elife.28482 · Cited by 75
Pinto, F., Pértega‐Gomes, N., Pereira, M. S., Vizcaino, J. R., Monteiro, P., Henrique, R., Baltazar, F., Andrade, R. P., & Reis, R. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0421 · Cited by 74
Danila, D. C., Anand, A., Schultz, N. D., Heller, G., Wan, M., Sung, C. C., Dai, C. S., Khanin, R., Fleisher, M., Lilja, H. G., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.006 · Cited by 74
Translating Genomics for Precision Cancer Medicine
Roychowdhury, S., & Chinnaiyan, A. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025552 · Cited by 75
Self-citationBarbieri, C. E., Chinnaiyan, A. M., Lerner, S. P., Swanton, C., & Rubin, M. A. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.024 · Cited by 74
Self-citationThe Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
Zheng, Z., Li, J., Liu, Y., Shi, Z., Xuan, Z., Yang, K., Xu, C., Bai, Y., Fu, M., Xiao, Q., et al. (2022) · Cancers · doi:10.3390/cancers14194877 · Cited by 77
Lochovsky, L., Zhang, J., Fu, Y., Khurana, E., & Gerstein, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv803 · Cited by 75
Beltran, H., Wyatt, A. W., Chedgy, E. C. P., Donoghue, A., Annala, M., Warner, E. W., Beja, K., Sigouros, M., Mo, F., Fazli, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1034 · Cited by 76
Wozniak, D. J., Kajdacsy‐Balla, A., Macias, V., Ball-Kell, S. M., Zenner, M. L., Bie, W., & Tyner, A. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01574-5 · Cited by 76
The prostate cancer genome: Perspectives and potential
Barbieri, C. E., & Tomlins, S. A. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.08.025 · Cited by 75
Self-citationGLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling
White, M. A., Tsouko, E., Lin, C., Rajapakshe, K., Spencer, J. M., Wilkenfeld, S. R., Vakili, S. S., Pulliam, T. L., Awad, D., Nikolos, F., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0051 · Cited by 74
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 88
Multilevel Mechanisms of Cancer Drug Resistance
Roszkowska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212402 · Cited by 73
ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation
Mahajan, K. N., & Mahajan, N. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.004 · Cited by 73
SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis
Ozturk, S., Papageorgis, P., Wong, C. K., Lambert, A. W., Abdolmaleky, H. M., Thiagalingam, A., Cohen, H. T., & Thiagalingam, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514663113 · Cited by 74
Wnt signaling in castration-resistant prostate cancer: implications for therapy.
Yokoyama, N. N., Shao, S., Hoang, B. H., Mercola, D., & Zi, X. (2014) · PubMed Central · Cited by 73
miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin
Das, D. K., Naidoo, M. K., Ilboudo, A., Park, J. Y., Ali, T. A., Krampis, K., Robinson, B. D., Osborne, J. R., & Ogunwobi, O. O. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.09.021 · Cited by 73
Ho, Y., & Dehm, S. M. (2017) · Endocrinology · doi:10.1210/en.2017-00109 · Cited by 73
Hu, J., Tian, J., Zhu, S., Sun, L., Yu, J., Tian, H., Dong, Q., Luo, Q., Jiang, N., Niu, Y., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.372 · Cited by 73
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
Ramnarine, V. R., Alshalalfa, M., Mo, F., Nabavi, N., Erho, N., Takhar, M. M., Shukin, R. J., Brahmbhatt, S., Gawronski, A., Kobelev, M., et al. (2018) · GigaScience · doi:10.1093/gigascience/giy050 · Cited by 73
Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer
Munkley, J., Li, L., Krishnan, S. R. G., Hysenaj, G., Scott, E., Dalgliesh, C., Oo, H. Z., Maia, T. M., Cheung, K., Ehrmann, I. E., et al. (2019) · eLife · doi:10.7554/elife.47678 · Cited by 73
Kawaguchi, K., Kinameri, A., Suzuki, S., Senga, S., Ke, Y., & Fujii, H. (2015) · Biochemical Journal · doi:10.1042/bj20150926 · Cited by 73
Metabolic adaptations in prostate cancer
Pujana-Vaquerizo, M., Bozal‐Basterra, L., & Carracedo, A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02762-z · Cited by 73
Saha, S. K., Islam, S. M. R., Kwak, K.-S., Rahman, M. S., & Cho, S. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0109-7 · Cited by 72
The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP
Hamilton, M. P., Rajapakshe, K., Bader, D. A., Cerne, J. Z., Smith, E. A., Coarfa, C., Hartig, S. M., & McGuire, S. E. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.008 · Cited by 71
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S. A., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 72
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Tsai, H. K., Morais, C. L., Alshalalfa, M., Tan, H., Haddad, Z., Hicks, J. L., Gupta, N., Epstein, J. I., Netto, G. J., Isaacs, W. B., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0744 · Cited by 71
Self-citationFOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression
Zhao, J. C., Fong, K.-W., Jin, H.-J., Yang, Y. A., Kim, J., & Yu, J. (2016) · Oncogene · doi:10.1038/onc.2015.496 · Cited by 71
Ruan, D., He, J., Li, C., Lee, H.-J., Liu, J., Lin, H.-K., & Chan, C. (2017) · Oncogene · doi:10.1038/onc.2017.64 · Cited by 72
Sagredo, A. I., Sagredo, E. A., Pola-Véliz, V., Echeverría, C., Andaur, R., Michea, L., Stutzin, A., Simón, F., Marcelain, K., & Armisén, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27371 · Cited by 71
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
